News
What happened, reported straight.
Three months after opening the rewrite for public comment, HHS has formally issued its 2026 Update to the National Plan to Address Alzheimer's Disease and Related Dementias, restructuring federal priorities around risk reduction, research, care and family support.
A fresh census of frontotemporal lobar degeneration trials finds the field has more than tripled since this paper last checked, with drugs and brain stimulation now splitting the pipeline evenly, even as two closely watched gene therapies quietly closed their doors this year.
Cognition Therapeutics said on October 22 that FDA neurology and psychiatry reviewers have agreed on how a future trial of zervimesine should be built: who qualifies, what dose, how long, and what counts as evidence. The agreement rests on an earlier, still-preliminary Phase 2 signal in dementia with Lewy bodies.
Empatica's wearable platform, now carrying algorithms from the Personal KinetiGraph system it bought in 2025, won FDA clearance on August 14, 2026. The clearance is a finding of equivalence to existing devices, not proof the device changes anyone's care.
Columbia researchers report that fibronectin, a structural protein, piles up around brain blood vessels in carriers of the Alzheimer's risk gene APOE4 and wears down the barrier that protects the brain. A rare genetic variant tied to protection in those same carriers appears to work by keeping that pileup in check.
A pilot analysis from the University of Washington Alzheimer's Disease Research Center split nearly 200 plasma samples between a national lab and its own, and the national lab's numbers ran consistently higher, even as the two sets of results tracked each other closely. The National Alzheimer's Coordinating Center reported the finding this month.
Pathologists at the University of Pennsylvania examined the donated brain of a man who took the anti-amyloid drug aducanumab for four and a half years. Where the drug had cleared plaque most thoroughly, tau tangles and tissue loss ran markedly lower than in neighboring patches of the same brain where amyloid never left.
A first-in-human trial at the University of California, San Francisco is imaging a transporter that sits almost entirely on astrocytes, the brain's housekeeping cells, to see whether their decline shows up before amyloid or tau does. So far, the only published results confirm the tracer is safe to give.
Filed September 24 and still sitting in committee with Booker as its only sponsor, S.Res.910 points to an estimated 1.4 million Americans living with Lewy body dementia and asks for more research and better-trained clinicians. It carries no funding and no legal weight.
A look at 1,110 people enrolled in the Alzheimer's Disease Neuroimaging Initiative found that those living in more economically deprived neighborhoods scored lower on a standard cognition test, and, among those with no signs of impairment, carried more amyloid protein on PET scans. The study is observational. It does not show that where someone lives causes amyloid to build up.
Block a receptor called P2X7, and a flood of inflammatory signaling in human brain cells and in tissue taken straight from neurosurgery recedes sharply. The scientists behind the finding call it a doorway toward future trials, not a drug sitting on a shelf today.
At a Philadelphia dementia conference, AviadoBio reported that cerebrospinal progranulin climbed higher at higher doses of its experimental gene therapy for a genetic form of frontotemporal dementia, while a blood marker of nerve injury held steady or eased in patients followed for a year.
A 50-person study asks a plain question: does a home dispenser that records every dose on video actually keep people with memory loss on their medication, or does it just add a camera to an old problem, giving caregivers proof instead of a guess.
Twenty four patients, 28 days, one experimental pill aimed at a protein called LRRK2. The company that made it says the eye and spinal fluid changes it found are worth watching, and says plainly the study cannot tell us whether anyone got better.
Two Mount Sinai studies using engineered human brain tissue report that APOE4, the strongest genetic risk factor for Alzheimer's, drives a specific, experimentally reversible pattern of blood vessel scarring and protein buildup, distinct from the gene's broader population-level risk.
A newly disclosed four-year readout of uniQure's gene therapy ifezuntirgene inilparvovec showed the trial's main statistical measure fell short of significance, reigniting questions about the small study's external comparison group even as the company's regulatory filing rests on earlier data.
AbbVie's once-daily tablet, sold as JUVMO, is the first Parkinson's medicine built to act on D1 and D5 dopamine receptors rather than the D2/D3 pathway used by older agonists; the FDA's September 28 clearance covers both early monotherapy and add-on use for motor fluctuations.
A statistics preprint from UNC Chapel Hill and Wake Forest puts four widely used models of time to Huntington's diagnosis through an external test in Enroll-HD data, using metrics built for cohorts where more than 80 percent of participants leave the study still undiagnosed.
A reanalysis of the pivotal Alzheimer's trials for both approved anti-amyloid drugs finds cognitive decline sped up, not slowed, once patients moved from blinded treatment into open-label extensions, nearing rates seen in the original placebo groups.
A new catalog built from more than 600 postmortem frontal cortex samples reports 1,067 previously unannotated small proteins, some altered in Alzheimer's disease independent of the genes long thought to be their only product.
A pooled analysis of more than 8,500 people without symptoms finds that adding APOE genotype to a plasma p-tau217 reading sharpens predictions of when cognitive symptoms will appear, the next step from the p-tau217 blood test cleared by regulators earlier this year.
The company said May 15 it will no longer enroll patients in its progranulin gene therapy trial, a month after the FDA told it a placebo-controlled, randomized trial would be required to seek approval for FTD-GRN.
C2N Diagnostics' PrecivityAD2 becomes the first FDA-cleared blood test for Alzheimer's biomarkers reaching symptomatic patients in their 40s, pushing the diagnostic category's age floor 15 years below prior clearances.
A community based study of 1,350 adults in their 50s and 60s found that plasma markers of Alzheimer's disease neuropathology tracked with weaker cognitive performance and faster decline in midlife, long before the age when the disease is usually diagnosed.
The ACTIVATE study of BIA 28-6156, an oral enzyme activator designed for Parkinson's patients carrying a GBA1 gene mutation, did not slow disease progression compared with placebo. Portuguese drugmaker Bial has stopped further development of the drug for this use.
Two newly built laboratory tests measuring the enzyme DOPA decarboxylase in spinal fluid distinguished Lewy body dementia and Parkinson's disease from Alzheimer's disease across several patient groups, a Nature Medicine study reports.
A University of British Columbia team has engineered a mouse carrying a patient's own GRN gene deletion, then used it to test a CRISPR based gene editing approach in living animals, in a paper published in Neurobiology of Disease.
Six weeks after the FDA cleared it, Eisai says the subcutaneous Leqembi Iqlik autoinjector is now available in the United States as a starting dose for early Alzheimer's disease, and China has approved the same formulation for initiation treatment, extending how much of the drug course can be given by injection at home rather than by IV infusion.
A peer-reviewed case report describes a Louisiana hunter's fatal, laboratory-confirmed sporadic Creutzfeldt-Jakob disease and the public health investigation triggered when a hunting-lodge peer developed similar illness; investigators found no evidence tying the cases to chronic wasting disease in local deer.
A retrospective analysis of United States health records finds that benzodiazepines and antipsychotics, not trazodone, dominate real-world prescribing for behavioral symptoms of frontotemporal dementia, even though the drugs linked to more emergency and hospital visits lack disease-specific trial evidence.
PROTECT-Cog, unveiled at AAIC 2026 in London with $100 million in funding, will test whether adding a metabolism-targeting drug to the U.S. POINTER lifestyle program does more to protect thinking skills in at-risk older adults than either approach alone.
A scoping review of three international trial registries found only twelve interventional studies worldwide testing disease-modifying drugs for frontotemporal dementia, split evenly between gene therapies for a rare inherited form and anti-inflammatory drugs aimed at the more common sporadic disease.
The Lewy Body Dementia Association has funded a new multi-site study, called Clin-Syn, led by researchers at UT Health San Antonio and the University of Florida, to determine what positive or negative alpha-synuclein biomarker results should mean for diagnosis and care.
An analysis of more than 200 African American brain donors found a gene called ADAMTS2 sharply overactive in Alzheimer's cases, and the same gene independently topped a comparable study of white patients, researchers say.
University of Eastern Finland researchers grew microglia from patient stem cells and found that immune cells from a genetic form of FTD and from the sporadic form change in different ways, with increased synapse-engulfing activity flagged as a possible driver of nerve cell loss.
A brain-imaging study of three cognitively healthy adult cohorts finds cortical thickness differences up to seven years before amyloid-PET scans turn positive, the marker now used to flag early Alzheimer's brain pathology.
A four-cohort genetic-epidemiology analysis calculates that the common APOE variants underlie roughly three-quarters to over nine-tenths of Alzheimer's disease cases, and close to half of all-cause dementia, a larger share than earlier estimates suggested.
A mouse study led by Lawrence Berkeley National Laboratory finds widespread breaks in DNA strands, separate from the disease's hallmark repeat expansion, kill brain cells, and that an experimental antioxidant compound reversed the damage in mice.
Full 18-month results from the CELIA trial, presented at the Alzheimer's Association International Conference in London, show diranersen outperformed placebo on cognition and function at three tested doses, though the study did not prove the dose-response effect it was designed to show.
An international cohort study of 278 people carrying C9orf72, GRN, or MAPT mutations pins survival on a combination of onset age, symptom domain, diagnosis type, disease stage at study entry, and region, not on the mutated gene alone.